- Home
- UTHR
as 06-18-2025 4:00pm EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 14.4B | IPO Year: | 1999 |
| Target Price: | $393.08 | AVG Volume (30 days): | 675.4K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 25.10 | EPS Growth: | 18.86 |
| 52 Week Low/High: | $266.98 - $417.81 | Next Earning Date: | 07-30-2025 |
| Revenue: | $2,994,100,000 | Revenue Growth: | 19.84% |
| Revenue Growth (this year): | 14.3% | Revenue Growth (next year): | 6.32% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Jun 12 '25 | Sell | $279.34 | 11,000 | $3,079,514.30 | 42,913 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Jun 2 '25 | Sell | $325.94 | 12,000 | $3,909,893.25 | 17,515 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | May 29 '25 | Sell | $314.94 | 11,000 | $3,476,765.35 | 42,913 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | May 15 '25 | Sell | $297.17 | 11,000 | $3,246,149.92 | 42,913 | |
| Thompson Tommy G | UTHR | Director | May 9 '25 | Sell | $305.15 | 2,500 | $762,865.00 | 8,480 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | May 1 '25 | Sell | $299.31 | 11,000 | $3,310,201.49 | 42,913 | |
| DWEK RAYMOND | UTHR | Director | Apr 21 '25 | Sell | $285.57 | 3,000 | $856,710.00 | 1,750 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Apr 17 '25 | Sell | $282.95 | 11,000 | $3,121,543.06 | 42,913 | |
| DWEK RAYMOND | UTHR | Director | Apr 14 '25 | Sell | $285.16 | 3,000 | $855,480.00 | 1,750 | |
| DWEK RAYMOND | UTHR | Director | Apr 7 '25 | Sell | $284.55 | 4,000 | $1,138,200.00 | 1,750 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing
Zacks
6 days ago
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?
StockStory
7 days ago
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to Keep Off Your Radar
Argus Research
7 days ago
Stock Market Adjusts to Tariff Turmoil
Zacks
8 days ago
Insmed Stock Jumps 29% on Encouraging PAH Study Results
Investor's Business Daily
9 days ago
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Zacks
9 days ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks
10 days ago
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.